Sun Pharma Advanced Research Company Limited (SPARC) has released the transcript of its Investor Call for the SPARC R&D Day, which focused on updates regarding prioritized programs. The call, held on January 08, 2026, provided insights into the company's strategy and pipeline progress. Key discussions included the company's narrowed therapeutic focus on oncology and immunology, with emphasis on two promising programs: a MUC1 ADC in solid tumors and a topical intervention for Alopecia Areata. SPARC is also exploring alternative structures like NewCos for certain developments, such as with Tiller Therapeutics for small molecule drug conjugates (SMDCs).

Significant updates were provided on SCD-153, a topical itaconate analog being evaluated for alopecia areata, with Phase 1B trial data expected in Q4 2026. The SBO-154 MUC1 target ADC program is advancing with Phase 1 dose escalation studies underway in solid tumors across the US, Australia, and India. The company also highlighted progress on its Pediatric Rare Disease Voucher (PRV) matter, with a court ruling in its favor and an appeal window nearing expiry by end of January. Furthermore, SPARC is working on PDP-716, a Brimonidine formulation, and has set up a NewCo for SCO-155, a PSMA-targeted SMDC, in collaboration with Tiller Therapeutics.

The company detailed its strategic shift towards targeted oncology, synthetic lethality, and derma autoimmune disorders. SPARC is developing modular platforms for targeted oncology, including ADCs with various payloads and T-cell engagers. In synthetic lethality, the focus is on agents that can sensitize tumors to radiation and chemotherapy or address PARP inhibitor resistance. For derma autoimmune disorders, SPARC is advancing SCD-153 as a potential alternative to current treatments. SPARC also addressed its cost optimization efforts, aiming for significant fixed cost savings through headcount reduction and operational streamlining, with a projected annual fixed cost saving of $10 million.